ADMA Biologics: Business Update And My Price Target (NASDAQ:ADMA)

Core Viewpoint - ADMA Biologics has been a favored stock for a significant period, with extensive coverage provided on Seeking Alpha, indicating strong interest and potential in the company [1]. Company Summary - ADMA Biologics has been the subject of nine articles written between 2021 and 2022, showcasing a consistent focus on the company's performance and prospects [1]. - The company is associated with a corporate lawyer, Jeffrey Himelson, who has a background in hedge funds and has gained recognition for his investment insights [1]. Analyst's Position - The analyst holds a beneficial long position in ADMA shares, indicating confidence in the company's future performance [2].